| Literature DB >> 31461150 |
Tianyang Zhang1,2,3, Anna Sidorchuk1,2, Laura Sevilla-Cermeño1,2,4, Alba Vilaplana-Pérez1,2,5, Zheng Chang3, Henrik Larsson3,6, David Mataix-Cols1,2, Lorena Fernández de la Cruz1,2.
Abstract
Importance: Birth by cesarean delivery is increasing globally, particularly cesarean deliveries without medical indication. Children born via cesarean delivery may have an increased risk of negative health outcomes, but the evidence for psychiatric disorders is incomplete. Objective: To evaluate the association between cesarean delivery and risk of neurodevelopmental and psychiatric disorders in the offspring. Data Sources: Ovid MEDLINE, Embase, Web of Science, and PsycINFO were searched from inception to December 19, 2018. Search terms included all main mental disorders in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). Study Selection: Two researchers independently selected observational studies that examined the association between cesarean delivery and neurodevelopmental and psychiatric disorders in the offspring. Data Extraction and Synthesis: Two researchers independently extracted data according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines and assessed study quality using the Newcastle-Ottawa Scale. Random-effects meta-analyses were used to pool odds ratios (ORs) with 95% CIs for each outcome. Sensitivity and influence analyses tested the robustness of the results. Main Outcomes and Measures: The ORs for the offspring with any neurodevelopmental or psychiatric disorder who were born via cesarean delivery compared with those were born via vaginal delivery.Entities:
Mesh:
Year: 2019 PMID: 31461150 PMCID: PMC6716295 DOI: 10.1001/jamanetworkopen.2019.10236
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Flow Diagram
aCharacteristics of these studies are presented in eTable 2 in the Supplement.
bSome studies address associations with more than 1 outcome.
Characteristics of the Studies Included in the Main Meta-analysis
| Source | Study | No. of Participants | Outcome(s) | Outcome Ascertainment | Age of Offspring | Newcastle -Ottawa Score | |||
|---|---|---|---|---|---|---|---|---|---|
| Location | Period | Design | Cesarean Delivery | Vaginal Delivery | |||||
| Matsuishi et al,[ | Japan | 1983-1987 | Case-control | 18 | 205 | Autistic disorder | 2-5 y | 4 | |
| Mrozek-Budzyn et al,[ | Poland | 2007 | Case-control | 74 | 204 | Childhood or atypical autism | 2-15 y | 5 | |
| Hamadé et al,83 2013 | Lebanon | 2012 | Case-control | 31872 | 84 023 | Autistic disorder | 3-27 y | 4 | |
| Maramara et al,[ | United States | 2000-2006 | Case-control | 31 872 | 84 023 | Autistic disorder, PDD-NOS, or Asperger syndrome | NR | 2 | |
| Burstyn et al,[ | Canada | 1998-2008 | Cohort | 49 456 | 170 572 | ASD | 4-10 y | 8 | |
| Axelsson et al,[ | Denmark | 1997-2014 | Cohort | 119 433 | 560 440 | ASD | 4-17 y | 9 | |
| Maimburg and Vaeth,[ | Denmark | 1990-1999 | Case-control | 633 | 4099 | Infantile autism | Mean age at diagnosis, 4.6 y | 8 | |
| Dodds et al,[ | Canada | 1990-2002 | Cohort | 26 754 | 102 948 | ASD | 2-15 y | 7 | |
| Chien et al,[ | Taiwan | 2004-2007 | Cohort | 174 376 | 362 297 | Infantile autism | 2-6 y | 9 | |
| Curran et al,[ | Sweden | 1982-2011 | Cohort | 340 108 | 2 357 206 | ASD | 4-29 y | 9 | |
| Guisso et al,[ | Lebanon | NR | Case-control | 125 | 189 | ASD | 2-18 y | 7 | |
| Yip et al,[ | Norway | 1984-2004 | Cohort | Norway: 127 922; Finland: 156 863; WA: 65 953 | Norway: 924 475; Finland: 891 684; WA: 279 228 | ASD | 5-25 y | 9 | |
| Finland | 1987-2004 | ||||||||
| WA | 1984-1999 | ||||||||
| Schieve et al,[ | United States | 1994-2002 | Case-control | NR | NR | ASD | 8 y | 6 | |
| 2000-2008 | |||||||||
| Haglund and Källén,[ | Sweden | 1980-2005 | Case-control | 7434 | 61 530 | Autistic disorder, childhood autism, Asperger syndrome | 2.5-20 y | 7 | |
| Chen et al,[ | Taiwan | 2005-2010 | Cohort | 6285 | 12 698 | Autism | 5.5 y | 9 | |
| Polo-Kantola et al,[ | Finland | 1990-2007 | Case-control | 3349 | 17 117 | Childhood autism, PDD, and Asperger syndrome | 2-17 y | 8 | |
| Duan et al,[ | China | 2011-2013 | Case-control | 287 | 285 | Childhood autism | 3-6 y | 5 | |
| Durkin et al,[ | United States | 1994-2008 | Case-control | 4624 | 26 843 | ASD including autistic disorder, PDD-NOS, and Asperger syndrome | 8 y | 7 | |
| Eriksson et al,[ | Sweden | 2002-2008 | Case-control | 23 286 | 94 242 | ASD | Clinical diagnosis | 20-54 mo | 5 |
| Hultman et al,[ | Sweden | 1974-1993 | Case-control | 352 | 2096 | Infantile autism | <10 y (mean age, 4.4 y for boys and 4.6 y for girls) | 8 | |
| Kissin et al,[ | United States | 1996-2011 | Cohort | 27 152 | 15 231 | Autistic disorder | 5 y | 6 | |
| Glasson et al,[ | Australia | 1980-1999 | Case-control | 380 | 1398 | ASD including autism, PDD-NOS, and Asperger syndrome | 4-19 y | 8 | |
| Zhang et al,[ | China | 2007 | Case-control | 77 | 104 | Autism | 3-21 y | 5 | |
| El-Baz et al,[ | Egypt | 2008-2010 | Case-control | 89 | 213 | Autism | 2-13 y | 4 | |
| Ji et al,[ | United States | 1998-2016 | Case-control | 214 | 434 | ASD | Median age at first ADHD diagnosis, 7 y | 6 | |
| Winkler-Schwartz et al,[ | Canada | 1991-2013 | Cohort | 35 | 48 | ASD | 3-17 y | 5 | |
| Al-Jammas and Al-Dobooni,[ | Iraq | 2011-2012 | Case-control | 19 | 81 | Autism, Asperger disorder, Rett syndrome | 1.5-7 y | 3 | |
| Çak and Gökler, [ | Turkey | 2003-2008 | Cohort | 80 | 12 | ADHD | K-SADS-PL and | 5 y | 5 |
| Murray et al,[ | United Kingdom, Brazil | ALSPAC:1991 to NR; Pelotas: 2004 to NR | Cohort | NR | NR | Any ADHD diagnosis including hyperactive-impulsive ADHD, inattentive ADHD, and combined ADHD | Development and well-being assessment based on | 7 y | 7 |
| Yeo et al,[ | South Korea | 2012-2013 | Case-control | 34 | 46 | ADHD | 6-12 y | 5 | |
| Gustafsson and Källén,[ | Sweden | 1986-1996 | Case-control | 2996 | 29 016 | ADHD | Age at diagnosis, 5 to 17 y | 6 | |
| Axelsson et al,[ | Denmark | 1997-2014 | Cohort | 117 863 | 553 727 | ADHD or attention-deficit disorder | 4-17 y | 8 | |
| Silva et al,[ | Australia | 1981-2003 | Case-control | 8863 | 34 829 | ADHD | 4-25 y | 8 | |
| Curran et al,[ | Sweden | 1990-2011 | Cohort | 238 687 | 1483 861 | ADHD | 3-21 y | 9 | |
| Sucksdorff et al,[ | Finland | 1991-2011 | Case-control | 8034 | 40 963 | ADHD | 2-20 y | 8 | |
| Chen et al,[ | Taiwan | 2005-2010 | Cohort | 6320 | 12 758 | ADHD | 5.5 y | 9 | |
| Ketzer et al,[ | Brazil | 2001-2007 | Case-control | NR | NR | ADHD–inattentive type | K-SADS-PL and | 6-17 y | 8 |
| Halmøy et al,[ | Norway | 1967-2005 | Case-control | 69051 | 1 103 345 | ADHD | 18-38 y | 8 | |
| Ji et al,[ | United States | 1998-2016 | Case-control | 267 | 525 | ADHD | Median age at first ADHD diagnosis, 7 y | 6 | |
| Amiri et al,[ | Iran | 2009 | Case-control | 162 | 168 | ADHD | K-SADS-PL | Mean age, 9.2 y for cases and 9.02 y for controls | 5 |
| Chen et al,[ | Taiwan | 2005-2010 | Cohort | 6360 | 12 825 | Learning disabilities | 5.5 y | 9 | |
| Sussmann et al,[ | United Kingdom | NR | Case-control | 16 | 74 | Intellectual disability | Wechsler Intelligence Scale and | 13-22 y | 6 |
| Bilder et al,[ | United States | 1994-2002 | Case-control | 2679 | 14 387 | Learning disabilities | 8 y | 7 | |
| Leivonen et al,[ | Finland | 1991-2010 | Case-control | 581 | 2961 | Tourette syndrome | NR | 8 | |
| Brander et al, [ | Sweden | 1973-2013 | Cohort | 336 063 | 2 611 439 | Tourette syndrome and chronic tic disorders | 10-40 y | 9 | |
| Cubo et al,[ | Spain | 2007-2009 | Case-control | 31 | 122 | Tic disorder | 6-16 y | 7 | |
| Razaz et and Cnattingius,[ | Sweden | 1992-2012 | Cohort | 53 807 | 428 768 | Anorexia nervosa | 10-20 y | 8 | |
| Cnattingius et al,[ | Sweden | 1973-1984 | Case-control | 387 | 4299 | Anorexia nervosa | 10-21 y | 7 | |
| Micali et al,[ | United Kingdom | NR | Cohort | NR | NR | Eating disorders | Eating Disorders Examination Questionnaire | Mean age at assessment, 20.8 y | 7 |
| Hvelplund et al,[ | Denmark | 1997-2010 | Cohort | 173 937 | 727 290 | Feeding and Eating disorder | 0-48 mo | 9 | |
| Brander et al,[ | Sweden | 1973-2013 | Cohort | 248 840 | 2 137 846 | OCD | 17-40 y | 9 | |
| Geller et al,[ | United States | NR | Case-control | 47 | 132 | OCD | K-SADS-PL, Children's Yale-Brown Obsessive Compulsive Scale, and | Mean age, 11.6 y | 5 |
| Vasconcelos et al,[ | Brazil | NR | Case-control | 47 | 91 | OCD | SCID-I/P and K-SADS | 11-44 y | 3 |
| Hultman et al,[ | Sweden | 1973-1994 | Case-control | 89 | 1099 | Affective psychoses | 15-21 y | 7 | |
| O'Neill et al,[ | Sweden | 1982-2011 | Cohort | 125 356 | 1 215 881 | Bipolar affective disorder, mania with psychotic symptoms, severe depressive episode with psychotic symptoms, and recurrent depressive disorder; current episode severe with psychotic symptoms | 16-29 y | 9 | |
| Bain et al,[ | United Kingdom | 1971-2000 | Case-control | NR | NR | Affective psychosis | 18-26 | 5 | |
| Chudal et al,[ | Finland | 1983-2008 | Case-control | 320 | 1792 | Bipolar disorder | 10-21 y | 8 | |
| Gourion et al,[ | Canada | 1986-2005 | Cohort | NR | NR | Major depressive disorder | 21 y | 8 | |
| Ordoñez et al,[ | United States | NR | Cohort | NR | NR | Childhood-onset schizophrenia | K-SADS-PL and | 12 y | 3 |
| Karlsson et al,[ | Sweden | 1975-2003 | Case-control | 85 | 679 | Schizophrenia, schizoaffective disorders, persistent delusional disorders, induced delusional disorder, acute and transient psychotic disorders, unspecified nonorganic psychosis, schizotypal disorder | <28 y | 7 | |
| Jones et al,[ | Finland | 1966-1993 | Case-control | 47 | 1097 | Schizophrenia | 16-28 y | 8 | |
| Harrison et al,[ | Sweden | 1973-1997 | Cohort | 60 110 | 635 915 | Nonaffective psychosis | 16-26 y | 7 | |
| O'Neill et al,[ | Sweden | 1982-2011 | Cohort | 125 155 | 1 213 931 | Schizophrenia, schizotypal disorder, persistent delusional disorders, acute and transient psychotic disorders, induced delusional disorder, schizoaffective disorders, other nonorganic psychotic disorders, and unspecified nonorganic psychosis | 16-29 y | 9 | |
| Kendell et al,[ | United Kingdom | 1971-1996 | Case-control | NR | NR | Schizophrenia | 18-25 y | 7 | |
| Byrne et al,[ | Ireland | 1972-1992 | Case-control | 15 | 832 | Schizophrenia | NR | 5 | |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; ASD, autism spectrum disorders; ATC, Anatomic Therapeutic Chemical; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Statistical Classification of Diseases and Related Health Problems; K-SADS, Kiddie Schedule for Affective Disorders and Schizophrenia; K-SADS-PL, Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Versions; NR, not reported; OCD, obsessive-compulsive disorder; PDD-NOS, pervasive developmental disorder–not otherwise specified; SCID-I/P, Structured Clinical Interview for DSM-IV, Axis I disorders–patient edition; WA, Western Australia.
Figure 2. Forest Plot of the Results of Random-Effects Meta-analyses Stratified by Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD)
Forest plot of odds ratios (ORs) in studies investigating the associations between cesarean delivery and each outcome. Diamonds show overall pooled estimate for each outcome. ALSPAC indicates Avon Longitudinal Study of Parents and Children; NA, not available.
Figure 3. Forest Plot of the Results of Random-Effects Meta-analyses Stratified by Intellectual Disability, Tic Disorder, Eating Disorder, Obsessive-Compulsive Disorder (OCD), Affective Psychosis/Depression, and Nonaffective Psychosis
Forest plot of odds ratios (ORs) in studies investigating the associations between cesarean delivery and each outcome. Diamonds show overall pooled estimate for each outcome. NA indicates not available.
Subgroup Analyses According to Proportion of Cesarean Deliveries, Study Quality Assessment, and Study Design for Neurodevelopmental and Psychiatric Disorders in Offspring Born via Cesarean Delivery Compared With Vaginal Delivery
| Outcome | Cesarean Delivery Use Proportion | Study Quality | Study Design | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <15% | ≥15% | High (NOS Score ≥7) | Low (NOS Score <7) | Cohort | Case-Control | |||||||||||
| No. of Studies | OR (95% CI) | No. of Studies | OR (95% CI) | No. of Studies | OR (95% CI) | No. of Studies | OR (95% CI) | No. of Studies | OR (95% CI) | No. of Studies | OR (95% CI) | |||||
| ADHD | 3 | 1.16 (1.03-1.31) | 8 | 1.22 (1.05-1.42) | .52 | 9 | 1.12 (1.05-1.21) | 5 | 1.37 (0.82-2.29) | .68 | 6 | 1.07 (0.98-1.18) | 8 | 1.29 (1.10-1.52) | .02 | |
| ASD | 8 | 1.29 (1.24-1.34) | 21 | 1.34 (1.22-1.48) | .02 | 16 | 1.30 (1.22-1.39) | 13 | 1.43 (1.22-1.68) | .81 | 11 | 1.28 (1.19-1.37) | 18 | 1.41 (1.29-1.55) | <.001 | |
| Psychoses | 9 | 1.00 (0.89-1.12) | 3 | 1.03 (0.52-2.03) | >.99 | 9 | 1.02 (0.93-1.12) | 3 | 1.14 (0.74-1.74) | .89 | 5 | 0.99 (0.88-1.12) | 7 | 1.18 (1.00-1.39) | .81 | |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; NOS, Newcastle-Ottawa Scale; OR, odds ratio.
Results of subgroup analyses on country income level and exposure ascertainment are reported in eTable 5 in the Supplement.
P values presented in the table are for group differences.
Study heterogeneity high (I2 > 75%; P < .05).
Study heterogeneity medium (I2 = 50%-75%; P < .05).